Biomarkers of acute kidney injury

Annual Review of Pharmacology and Toxicology

Volumn 48, Issue , 2008, Pages 463-493

  Vaidya, Vishal S ^a   Ferguson, Michael A ^b   Bonventre, Joseph V ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acute renal failure; Clusterin; Cystatin C; Cysteine rich protein 61 (CYR 61); ELISA; Interleukin 18 (IL 18); Kidney injury molecule 1 (Kim 1); Microfluidics; Nanotechnology; Neutrophil gelatinase associated lipocalin (NGAL)

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALPHA 1 MICROGLOBULIN; ANALGESIC AGENT; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CISPLATIN; CLUSTERIN; CONTRAST MEDIUM; CREATININE; CYCLOSPORIN; CYSTATIN C; CYSTEINE RICH PROTEIN 61; FATTY ACID BINDING PROTEIN; FETUIN A; GAMMA GLUTAMYLTRANSFERASE; GENTAMICIN; GLUTATHIONE TRANSFERASE ALPHA; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; MICROSOMAL AMINOPEPTIDASE; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPONTIN; RETINOL BINDING PROTEIN; SODIUM PROTON EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN 3; TACROLIMUS; TOBRAMYCIN;

ACUTE KIDNEY FAILURE; CELL SURVIVAL; CLINICAL EVALUATION; CLINICAL STUDY; COLORIMETRY; CREATININE BLOOD LEVEL; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE MARKER; DRUG SAFETY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS FILTRATION RATE; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; IMMUNOBLOTTING; INJURY SEVERITY; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PERFUSION; KIDNEY TUBULE EXCRETION; MEDICAL DECISION MAKING; MICROALBUMINURIA; NANOTECHNOLOGY; NEPHELOMETRY; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; VALIDATION PROCESS; WESTERN BLOTTING; ANIMAL; CLINICAL TRIAL; DRUG SCREENING; METHODOLOGY;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; RENAL INSUFFICIENCY, ACUTE;

EID: 41149106514     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.48.113006.094615     Document Type: Review

References (144)

1. Warnock DG. 2005. Towards a definition and classification of acute kidney injury. J. Am. Soc. Nephrol. 16:3149-50
2. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, et al. 2007. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11:R31
3. Chertow GM, Lee J, Kuperman GJ, Burdick E, Horsky J, et al. 2001. Guided medication dosing for inpatients with renal insufficiency. JAMA 286:2839-44
4. Liangos O, Wald R, O'Bell JW, Price L, Pereira BJ, Jaber BL. 2006. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin. J. Am. Soc. Nephrol. 1:43-51
5. de Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, et al. 2000. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 26:915-21
6. Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM. 2006. Declining mortality in patients with acute renal failure, 1988 to 2002. J. Am. Soc. Nephrol. 17:1143-50
7. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, et al. 2005. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294:813-18
8. Nash K, Hafeez A, Hou S. 2002. Hospital-acquired renal insufficiency. Am. J. Kidney Dis. 39:930-36
9. Thadhani R, Pascual M, Bonventre JV. 1996. Acute renal failure. N. Engl. J. Med. 334:1448-60
10. Choudhury D, Ziauddin A. 2005. Drug-associated renal dysfunction and injury. Nat. Clin. Pract. Nephrol. 2:80-91
11. Kleinknecht D, Landais P, Goldfarb B. 1987. Drug-associated acute renal failure. A prospective collaborative study of 81 biopsied patients. Adv. Exp. Med. Biol. 212:125-28
12. Bonventre JV, Weinberg JM. 2003. Recent advances in the pathophysiology of ischemic acute renal failure. J. Am. Soc. Nephrol. 14:2199-210
13. Schrier RW, Wang W, Poole B, Mitra A. 2004. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J. Clin. Invest. 114:5-14
14. Zuk A, Bonventre JV, Brown D, Madin KS. 1998. Polarity, integrin, and extracellular matrix dynamics in the postischemic rat kidney. Am. J. Physiol. Cell Physiol. 275:C711-31
15. Zuk A, Bonventre JV, Matlin KS. 2001. Expression of fibronectin splice variants in the postischemic rat kidney. Am. J. Physiol. Renal. Physiol. 280:F1037-53
16. Bonventre JV, Zuk A. 2004. Ischemic acute renal failure: an inflammatory disease? Kidney Int. 66:480-85
17. Park KM, Byun JY, Kramers C, Kim JI, Huang PL, Bonventre JV. 2003. Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. J. Biol. Chem. 278:27256-66
18. Humphreys BD, Bonventre JV. 2007. The contribution of adult stem cells to renal repair. Nephrol. Ther. 3:3-10
19. Bonventre JV. 2003. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J. Am. Soc. Nephrol. 14(Suppl. 1):S55-61
20. Humphreys BD, Bonventre JV. 2008. Mesenchymal stem cells in acute kidney injury. Annu. Rev. Med. 59:325-39
21. Vaidya VS, Shankar K, Lock EA, Bucci TJ, Mehendale HM. 2003. Renal injury and repair following S-1, 2 dichlorovinyl-L-cysteine administration to mice. Toxicol. Appl. Pharmacol. 188:110-21
22. Kellum JA, Levin N, Bouman C, Lameire N. 2002. Developing a consensus classification system for acute renal failure. Curr. Opin. Crit. Care. 8:509-14
23. Mehta RL, Chertow GM. 2003. Acute renal failure definitions and classification: time for change? J. Am. Soc. Nephrol. 14:2178-87
24. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. 2004. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8:R204-12
25. Mehta RL, Kellum JA, Shah S, Molitoris BA, Ronco C, et al. 2006. AKIN: Acute Kidney Injury Network: report of an initiative. In AKIN Summit. Amsterdam: AKIN Comm.
26. Moran SM, Myers BD. 1985. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int. 27:928-37
27. Star RA. 1998. Treatment of acute renal failure. Kidney Int. 54:1817-31
28. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. 2004. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8:R204-12
29. Vaidya VS, Bonventre JV. 2006. Mechanistic biomarkers for cytotoxic acute kidney injury. Expert. Opin. Drug. Metab. Toxicol. 2:697-713
30. Emeigh Hart SG. 2005. Assessment of renal injury in vivo. J. Pharmacol. Toxicol. Methods 52:30-45
31. Ikenaga H, Suzuki H, Ishii N, Itoh H, Saruta T. 1993. Enzymuria in noninsulin-dependent diabetic patients: signs of tubular cell dysfunction. Clin. Sci. (London) 84:469-75
32. Ascione R, Lloyd CT, Underwood MJ, Gomes WJ, Angelini GD. 1999. On-pump versus off-pump coronary revascularization: evaluation of renal function. Ann. Thorac. Surg. 68:493-98
33. Westhuyzen J, Endre ZH, Reece G, Reith DM, Saltissi D, Morgan TJ. 2003. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol. Dial. Transplant. 18:543-51
34. Chew SL, Lins RL, Daelemans R, Nuyts GD, De Broe ME. 1993. Urinary enzymes in acute renal failure. Nephrol. Dial. Transplant. 8:507-11
35. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, et al. 2007. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J. Am. Soc. Nephrol. 18:904-12
36. Bondiou MT, Bourbouze R, Bernard M, Percheron F, Perez-Gonzalez N, Cabezas JA. 1985. Inhibition of A and B N-acetyl-beta-D-glucosaminidase urinary isoenzymes by urea. Clin. Chim. Acta. 149:67-73
37. Vaidya VS, Shankar K, Lock EA, Bucci TJ, Mehendale HM. 2003. Role of tissue repair in survival from s-(1,2-dichlorovinyl)-L-cysteine-induced acute renal tubular necrosis in the mouse. Toxicol. Sci. 74:215-27
38. Iqbal MP, Ali AA, Waqar MA, Mehboobali N. 1998. Urinary N-acetyl-beta-D-glucosaminidase in rheumatoid arthritis. Exp. Mol. Med. 30:165-69
39. Fujita H, Narita T, Morii T, Shimotomai T, Yoshioka N, et al. 2002. Increased urinary excretion of N-acetylglucosaminidase in subjects with impaired glucose tolerance. Ren. Fail. 24:69-75
40. Tominaga M, Fujiyama K, Hoshino T, Tanaka Y, Takeuchi T, et al. 1989. Urinary N-acetyl-beta-D-glucosaminidase in the patients with hyperthyroidism. Horm. Metab. Res. 21:438-40
41. Tolkoff-Rubin NE, Rubin RH, Bonventre JV. 1988. Noninvasive renal diagnostic studies. Clin. Lab. Med. 8:507-26
42. Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C. 1998. Beta-2 microglobulin in renal disease. J. Am. Soc. Nephrol. 9:1723-35
43. Chapelsky MC, Nix DE, Cavanaugh JC, Wilton JH, Norman A, Schentag JJ. 1992. Renal tubular enzyme effects of clarithromycin in comparison with gentamicin and placebo in volunteers. Drug. Saf. 7:304-9
44. Dehne MG, Boldt J, Heise D, Sablotzki A, Hempelmann G. 1995. Tamm-Horsfall protein, alpha-1- and beta-2-microglobulin as kidney function markers in heart surgery. Anaesthesist 44:545-51
45. Schaub S, Wilkins JA, Antonovici M, Krokhin O, Weiler T, et al. 2005. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am. J. Transplant: 5:729-38
46. Davey PG, Gosling P. 1982. Beta 2-microglobulin instability in pathological urine. Clin. Chem. 28:1330-33
47. Herget-Rosenthal S, Poppen D, Husing J, Marggraf G, Pietruck F, et al. 2004. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin. Chem. 50:552-58
48. Wolf MW, Boldt J. 2007. Kidney specific proteins: markers for detection of renal dysfunction after cardiac surgery? Clin. Res. Cardiol. Suppl. 2:S103-7
49. Ojala R, Ala-Houhala M, Harmonien AP, Luukkaala T, Uotila J, Tammela O. 2006. Tubular proteinuria in preterm and full-term infants. Pediatr. Nephrol. 21:68-73
50. Penders J, Delanghe JR. 2004. Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin. Chim. Acta 346:107-18
51. Bernard AM, Vyskocil AA, Mahieu P, Lauwerys RR. 1987. Assessment of urinary retinol-binding protein as an index of proximal tubular injury. Clin. Chem. 33:775-79
52. Roberts DS, Haycock GB, Dalton RN, Turner C, Tomlinson P, et al. 1990. Prediction of acute renal failure after birth asphyxia. Arch. Dis. Child. 65:1021-28
53. Garcon G, Leleu B, Zerimech F, Marez T, Haguenoer JM, et al. 2004. Biologic markers of oxidative stress and nephrotoxicity as studied in biomonitoring of adverse effects of occupational exposure to lead and cadmium. J. Occup. Environ. Med. 46:1180-6
54. D'Amico G, Bazzi C. 2003. Urinary protein and enzyme excretion as markers of tubular damage. Curr. Opin. Nephrol. Hypertens. 12:639-43
55. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, et al. 2005. Cystatin C and the risk of death and cardiovascular events among elderly persons. N. Engl. J. Med. 352:2049-60
56. Bokenkamp A, Ciarimboli G, Dieterich C. 2001. Cystatin C in a rat model of end-stage renal failure. Ren. Fail. 23:431-38
57. Conti M, Moutereau S, Zater M, Lallali K, Durrbach A, et al. 2006. Urinary cystatin C as a specific marker of tubular dysfunction. Clin. Chem. Lab. Med. 44:288-91
58. Russo LM, Sandoval RM, McKee M, Osicka TM, Collins AB, et al. 2007. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int. 71:504-13
59. Kern W, Braess J, Kaufmann CC, Wilde S, Schleyer E, Hiddemann W. 2000. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection. Anticancer Res. 20:3679-88
60. Koch Nogueira PC, Hadj-Aissa A, Schell M, Dnbourg L, Brunat-Mentigny M, Cochat P. 1998. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. Pediatr. Nephrol. 12:572-75
61. Tugay S, Bircan Z, Caglayan C, Arisoy AE, Gokalp AS. 2006. Acute effects of gentamicin on glomerular and tubular functions in preterm neonates. Pediatr. Nephrol. 21:1389-92
62. Levin A, Pate GE, Shalansky S, Al-Shamari A, Webb JG, et al. 2007. N-acetylcysteine reduces urinary albumin excretion following contrast administration: evidence of biological effect. Nephrol. Dial. Transplant 22:2520-24
63. Uchida K, Gotoh A. 2002. Measurement of cystatin-C and creatinine in urine. Clin. Chim. Acta 323:121-28
64. Herget-Rosenthal S, Pietruck F, Volbracht L, Philipp T, Kribben A. 2005. Serum cystatin C - a superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine. Clin. Nephrol. 64:41-46
65. Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, et al. 1994. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin. Chem. 40:1921-26
66. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, et al. 1998. Kidney injury molecule-1 (KTM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 273:4135-42
67. Bailly V, Zhang Z, Meier W, Cate R, Sanicola M, Bonventre JV. 2002. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J. Biol. Chem. 277:39739-48
68. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. 2006. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am. J. Physiol. Renal Physiol. 290:F517-29
69. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. 2002. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 62:237-44
70. Vaidya VS, Ramirez V, Bobadilla NA, Bonventre JV. 2005. A microfluidics based assay to measure Kidney injury molecule-1 (Kim-1) in the urine as a biomarker for early diagnosis of acute kidney injury. J. Am. Soc. Nephrol. 16:192A
71. Dieterle F, Staedtler F, Grenet O, Cordier A, Perentes E, et al. 2007. Qualification of biomarkers for regulatory decision making - a kidney safety biomarker project. Toxicol. Off. J. Soc. Toxicol. 96:381
72. Prozialeck WC, Vaidya VS, Liu J, Waalkes MP, Edwards JR, et al. 2007. Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney Int. 72:985-93
73. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, et al. 2007. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J. Am. Soc. Nephrol. 18:904-12
74. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. 2 007. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J. Pathol. 212:209-17
75. Blaschuk O, Burdzy K, Fritz IB. 1983. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J. Biol. Chem. 258:7714-20
76. Rosenberg ME, Paller MS. 1991. Differential gene expression in the recovery from ischemic renal injury. Kidney Int. 39:1156-61
77. Witzgall R, Brown D, Schwarz C, Bonventre JV. 1994. Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J. Clin. Invest. 93:2175-88
78. Chevalier RL. 1996. Growth factors and apoptosis in neonatal ureteral obstruction. J. Am. Soc. Nephrol. 7:1098-105
79. Davis JW 2nd, Goodsaid FM, Bral CM, Obert LA, Mandakas G, et al. 2004. Quantitative gene expression analysis in a nonhuman primate model of antibiotic-induced nephrotoxicity. Toxicol. Appl. Pharmacol. 200:16-26
80. Kharasch ED, Schroeder JL, Bammler T, Beyer R, Srinouanprachanh S. 2006. Gene expression profiling of nephrotoxicity from the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether ("Compound A") in rats. Toxicol. Sci. 90:419-31
81. Harding MA, Chadwick LJ, Gattone VH 2nd, Calvet JP. 1991. The SGP-2 gene is developmentally regulated in the mouse kidney and abnormally expressed in collecting duct cysts in polycystic kidney disease. Dev. Biol. 146:483-90
82. Correa-Rotter R, Ibarra-Rubio ME, Schwochau G, Cruz C, Silkensen JR, et al. 1998. Induction of clusterin in tubules of nephrotic rats. J. Am. Soc. Nephrol. 9:33-37
83. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, et al. 2006. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 13:12-19
84. Aulitzky WK, Schlegel PN, Wu DF, Cheng CY, Chen CL, et al. 1992. Measurement of urinary clusterin as an index of nephrotoxicity. Proc. Soc. Exp. Biol. Med. 199:93-96
85. Silkensen JR, Agarwal A, Nath KA, Manivel JC, Rosenberg ME. 1997. Temporal induction of clusterin in cisplatin nephrotoxicity. J. Am. Soc. Nephrol. 8:302-5
86. Borregaard N, Sehested M, Nielsen BS, Sengelov H, Kjeldsen L. 1995. Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation. Blood 85:812-17
87. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. 1996. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 38:414-20
88. Flower DR, North AC, Sansom CE. 2000. The lipocalin protein family: structural and sequence overview. Biochim. Biophys. Acta 1482:9-24
89. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, et al. 2005. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest. 115:610-21
90. Cowland JB, Borregaard N. 1997. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 45:177-23
91. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, et al. 2003. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 14:2534-43
92. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, et al. 2005. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest. 115:610-21
93. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, et al. 2006. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA 103:1834-39
94. Matthaeus T, Schulze-Lohoff E, Ichimura T, Weber M, Andreucci M, et al. 2001. Co-regulation of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in the postischemic rat kidney. J. Am. Soc. Nephrol. 12: 787A
95. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. 2004. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol. 24:307-15
96. Wagener G, Jan M, Kim M, Mori K, Barasch JM, et al. 2006. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 105:485-91
97. Trachtman Fl, Christen E, Cnaan A, Patrick J, Mai V, et al. 2006. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr. Nephrol. 21:989-94
98. Ohlsson S, Wieslander J, Segelmark M. 2003. Increased circulating levels of proteinase 3 in patients with antineutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission. Clin. Exp. Immunol. 131:528-35
99. Xu SY, Pauksen K, Venge P. 1995. Serum measurements of human neutrophil lipocalin (HNL) discriminate between acute bacterial and viral infections. Scand. J. Clin. Lab. Invest. 55:125-31
100. Nakamura K, Okamura H, Nagata K, Komatsu T, Tamura T. 1993. Purification of a factor which provides a costimulatory signal for gamma interferon production. Infect. Immun. 61:64-70
101. Gracie JA, Robertson SE, McInnes IB. 2003. Interleukin-18. J. Leukoc. Biol. 73:213-24
102. Sugawara I. 2000. Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens. Microbes Infect. 2:1257-63
103. Leslie JA, Rink RC, Meldrum KK. 2007. The role of interleukin-18 in renal injury. J. Surg. Res.
104. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. 2004. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am. J. Kidney Dis. 43:405-14
105. Striz I, Krasna E, Honsova E, Lacha J, Petrickova K, et al. 2005. Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. Immunol. Lett. 99:30-35
106. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. 2005. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J. Am. Soc. Nephrol. 16:3046-52
107. Yang GP, Lau LF. 1991. Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ. 2:351-57
108. Perbal B. 2001. The CCN family of genes: a brief history. Mol. Pathol. 54:103-4
109. Muramatsu Y, Tsujie M, Kohda Y, Pham B, Perantoni AO, et al. 2002. Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int. 62:1601-10
110. Xie Y, Nishi S, Iguchi S, Imai N, Sakatsume M, et al. 2001. Expression of osteopontin in gentamicin-induced acute tubular necrosis and its recovery process. Kidney Int. 59:959-74
111. Asplin JR, Arsenault D, Parks JH, Coe FL, Hoyer JR. 1998. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int. 53:194-99
112. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. 2001. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 60:1645-57
113. Hudkins KL, Giachelli CM, Cui Y, Couser WG, Johnson RJ, Alpers CE. 1999. Osteopontin expression in fetal and mature human kidney. J. Am. Soc. Nephrol. 10444-57
114. Thomas SE, Lombardi D, Giachelli C, Bohle A, Johnson RJ. 1998. Osteopontin expression, tubulointerstitial disease, and essential hypertension. Am. J. Hypertens. 11:954-61
115. Hudkins KL, Giachelli CM, Eimer F, Couser WG, Johnson RJ, Alpers CE. 2000. Osteopontin expression in human crescentic glomerulonephritis. Kidney Int. 57:105-16
116. Mezzano SA, Droguett MA, Burgos ME, Ardiles LG, Aros CA, et al. 2000. Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy. Kidney Int. 57:147-58
117. Okada H, Moriwaki K, Konishi K, Kobayashi T, Sugahara S, et al. 2000. Tubular osteopontin expression in human glomerulonephritis and renal vasculitis. Am. J. Kidney Dis. 36:498-506
118. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. 2001. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 60:1645-57
119. Glatz JF, Van Der Vusse GJ. 1996. Cellular fatty acid-binding proteins: their function and physiological significance. Prog. Lipid. Res. 35:243-82
120. Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH. 1992. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem. J. 288(Pt. 1):285-90
121. Maatman RG, Van Kuppevelt TH, Veerkamp JH. 1991. Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem. J. 273(Pt. 3):759-66
122. Sweetser DA, Heuckeroth RO, Gordon JI. 1987. The metabolic significance of mammalian fatty-acid-binding proteins: abundant proteins in search of a function. Annu. Rev. Nutr. 7:337-59
123. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, et al. 2004. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J. Lab. Clin. Med. 143:23-30
124. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, et al. 2006. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol. Cell. Biochem. 284:175-82
125. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, et al. 2004. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am. J. Pathol. 165:1243-55
126. Nakamura T, Sugaya T, Ebihara I, Koide H. 2005. Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy. Am. J. Nephrol. 25:447-50
127. Nakamura T, Sugaya T, Node K, Ueda Y, Koide H. 2006. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am. J. Kidney Dis. 47:439-44
128. du Cheyron D, Daubin C, Poggioli J, Ramakers M, Houillier P, et al. 2003. Urinary measurement of Na+/H+exchanger isoform 3 (NHE3) protein as new marker of tubule injury in critically ill patients with ARF. Am. J. Kidney Dis. 42497-506
129. Wang T, Yang CL, Abbiati T, Schultheis PJ, Shull GE, et al. 1999. Mechanism of proximal tubule bicarbonate absorption in NHE3 null mice. Am. J. Physiol. Renal Physiol. 277:F298-302
130. Eladari D, Leviel F, Pezy F, Paillard M, Chambrey R. 2002. Rat proximal NHE 3 adapts to chronic acid-base disorders but not to chronic changes in dietary NaCl intake. Am. J. Physiol. Renal Physiol. 282:F835-43
131. McKee JA, Kumar S, Ecelbarger CA, Fernandez-Llama P, Terris J, Knepper MA. 2000. Detection of Na(+) transporter proteins in urine. J. Am. Soc. Nephrol. 11:2128-32
132. Zhou H, Yuen PS, Pisitkun T, Gonzales PA, Yasuda H, et al. 2006. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int. 69:1471-76
133. Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W. 2003. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and feruin-A. Biochem. J. 376:135-45
134. Zhou H, Pisitkun T, Aponte A, Yuen PS, Hoffert JD, et al. 2006. Exosomal fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int. 70:1847-57
135. Cheruvanky A, Zhou H, Pisitkun T, Kopp JB, Knepper MA, et al. 2007. Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. Am. J. Physiol. Renal Physiol. 292(5):F1657-61
136. Carson RT, Vignali DA. 1999. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J. Immunol. Methods 227:41-52
137. Vignali DA. 2000. Multiplexed particle-based flow cytometric assays. J. Immunol. Methods 243:243-55
138. Hu H, Aizenstein BD, Puchalski A, Burmania JA, Hamawy MM, Knechde SJ. 2004. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am. J. Transplant. 4:432-37
139. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, et al. 2005. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51:336-45
140. Wang WU, Chen C, Lin KH, Fang Y, Lieber CM. 2005. Label-free detection of small-molecule-protein interactions by using nanowire nanosensors. Proc. Natl. Acad. Sci. USA 102:3208-12
141. Zheng G, Patolsky F, Cui Y, Wang WU, Lieber CM. 2005. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat. Biotechnol. 23:1294-301
142. Patolsky F, Zheng G, Lieber CM. 2006. Fabrication of silicon nanowire devices for ultrasensitive, label-free, real-time detection of biological and chemical species. Nat. Protoc. 1:1711-24
143. Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, et al. 2007. Advances in urinary proteome analysis and biomarker discovery. J. Am. Soc. Nephrol. 18(4)4057-71
144. Rifai N, Gillette MA, Carr SA. 2006. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24:971-83